HKUST and PhIRDA Sign MoU to Establish Innovation Centers
The Hong Kong University of Science and Technology (HKUST) and the China Pharmaceutical Innovation and...
China Releases Blue Book on Medical Insurance Fund Supervision
The China Health Insurance and Social Sciences Academic Press has jointly released the “Blue Book...
NHC Recommends Simcere and Junshi COVID-19 Therapies in Updated Guidelines
The National Health Commission (NHC) has released a notification including Simcere Pharmaceutical Group’s (HKG: 2096)...
ClinChoice Acquires Cromsource to Expand Global CRO Footprint
Sino-US Contract Research Organization (CRO) ClinChoice Medical Development has announced the acquisition of Cromsource S.r.l.,...
Atom Bioscience’s ABP-671 Shows Positive Phase IIa Results in Gout Treatment
China-based Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd) has announced positive results from...
Echo Biotech Secures Series A++ Funding for Exosomes Drug Development
Echo Biotech, a Beijing-based exosomes drug developer, has reportedly raised “tens of millions” of renminbi...
AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...
National VBP Tender Round 8 to Be Held in Hainan with 40 Drugs Bidding
The National Allied Procurement Office has released a notification regarding the Round 8 of the...
TinKer Bio Raises Series A+ Funding for Microfluidic Chip Expansion
China-based Hangzhou TinKer BioTechnology Co., Ltd, a leading microfluidic chip technology platform company, has reportedly...
OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...
Hexin Medical Technology Raises Series A Funding for Radionuclide Therapy
Hexin Medical Technology Co., Ltd, a radionuclide therapy developer based in Suzhou, has reportedly raised...
Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...
TandemAI Secures $35M Series A to Expand Drug Discovery Platform
TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...
Merck Reports 12.9% Sales Growth in 2022 Annual Report
German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...
NHSA Releases Guidelines on Drug Procurement and Pricing Management
The National Healthcare Security Administration (NHSA) has released a notification regarding provincial centralized procurement and...
Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib
Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...
Zai Lab Reports 2022 Financial Results with Revenue Growth
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...
Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development
Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...
Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study
China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...